Clinical Trials Directory

Trials / Unknown

UnknownNCT04270240

A NEW SCORING SYSTEM FOR PREDICTION OF PDA

Can a New Scoring System Predict Hemodynamically Significant PDA Diagnosis and Treatment Requirement for Extremely Preterm Newborns Earlier

Status
Unknown
Phase
Study type
Observational
Enrollment
100 (estimated)
Sponsor
Kanuni Sultan Suleyman Training and Research Hospital · Academic / Other
Sex
All
Age
15 Days
Healthy volunteers
Not accepted

Summary

Patent ductus arteriosus (PDA) is an important morbidity of that the diagnosis and treatment is controversy in premature infants. A number of scoring systems have been developed, including the findings of echocardiography on the diagnosis and treatment of PDA. This study aimed to develop a new clinical scoring system that will enable the rapid, standard and noninvasive evaluation of hemodynamically significant PDA earlier, without relying on echocardiographic findings in premature babies with extremely low birth weight, and to determine the role of this scoring system in early diagnosis and treatment.

Detailed description

This study aimed to develop a new clinical scoring system that will enable the rapid, standard and noninvasive evaluation of hemodynamically significant PDA earlier, without relying on echocardiographic findings in premature babies with extremely low birth weight, and to determine the role of this scoring system in early diagnosis and treatment.

Conditions

Timeline

Start date
2019-01-15
Primary completion
2020-12-15
Completion
2021-02-15
First posted
2020-02-17
Last updated
2020-05-06

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT04270240. Inclusion in this directory is not an endorsement.